Bristol Myers expands Celgene-era deal with Exscientia, taking its AI R&D engine to the next step
One day after taking a shot on an anti-TIGIT bispecific from Agenus, Bristol Myers Squibb is still in a dealmaking mood.
For Wednesday’s chaser, Bristol Myers is returning to a company that had teamed up with Celgene before its acquisition in 2019. That biotech is Exscientia, and they’ve scored an expanded deal with Bristol Myers to further build on its artificial intelligence capabilities less than a month after a massive Series D financing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.